BioSpace News Archive

CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights new activities and the use of CytoSorb in sepsis patien

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, Aura Biosciences, has dosed the first patient in its Phase 2 clinical trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroidal melanoma.

Prothena Corporation plc (NASDAQ:PRTA), announced that results from the Phase 2 PASADENA study of prasinezumab are being highlighted today at the International Parkinson and Movement Disorder Society’s MDS Virtual Congress 2020 (MDS Congress).

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company’s Board of Directors.

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Co-Founder and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference

The COVID-19 pandemic has created an overwhelming demand for testing, with laboratories nationwide seeing, on average, testing volumes at 1.6 times their normal levels.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.18 per share.

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company today announced a strategic partnership agreement with Hualan Genetic Engineering Co., Ltd (Hualan Genetic) to develop HBM’s three proprietary innovative monoclonal and bispecific antibodies.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the J.P. Morgan 11th Annual U.S. All Stars Conference on Wednesday, September 16, 2020 at 1:00 p.m. EDT.